These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34084110)

  • 1. Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Case Series with Review of the Literature.
    Al-Dosari YM; Al-Zahrani H; Al-Mohareb F; Hashmi S
    Saudi J Med Med Sci; 2021; 9(2):178-189. PubMed ID: 34084110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy in Classical Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia-Paroxysmal Nocturnal Hemoglobinuria: A High-Risk Constellation.
    Alashkar F; Saner FH; Vance C; Schmücker U; Herich-Terhürne D; Dührsen U; Köninger A; Röth A
    Front Med (Lausanne); 2020; 7():543372. PubMed ID: 33102497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review.
    Zhang B; Chu R; Huang C; Song X; Wang J; Li L; Xu Y; Ma Y
    J Womens Health (Larchmt); 2024 Jan; 33(1):98-104. PubMed ID: 37917919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review.
    Miyasaka N; Miura O; Kawaguchi T; Arima N; Morishita E; Usuki K; Morita Y; Nishiwaki K; Ninomiya H; Gotoh A; Imashuku S; Urabe A; Shichishima T; Nishimura J; Kanakura Y
    Int J Hematol; 2016 Jun; 103(6):703-12. PubMed ID: 26857155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
    Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
    Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of paroxysmal nocturnal hemoglobinuria in pregnancy with eculizumab: A case report.
    Fassett MJ; Hernandez Lopez AL
    Case Rep Womens Health; 2021 Apr; 30():e00294. PubMed ID: 33665137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Japanese patient preferences between ravulizumab and eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria].
    Ishiyama K; Usuki K; Ikezoe T; Gotoh A; Myren KJ; Tomazos I; Shimono A; Ninomiya H; Sakurai M; Nakao S; Nishimura JI
    Rinsho Ketsueki; 2023; 64(1):9-17. PubMed ID: 36775313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
    Cooper JP; Farah RJ; Stevenson PA; Gooley TA; Storb R; Scott BL
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1331-1339. PubMed ID: 30711779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria.
    Stern RM; Connell NT
    Ther Adv Hematol; 2019; 10():2040620719874728. PubMed ID: 31534662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria.
    Kelly RJ; Höchsmann B; Szer J; Kulasekararaj A; de Guibert S; Röth A; Weitz IC; Armstrong E; Risitano AM; Patriquin CJ; Terriou L; Muus P; Hill A; Turner MP; Schrezenmeier H; Peffault de Latour R
    N Engl J Med; 2015 Sep; 373(11):1032-9. PubMed ID: 26352814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of current treatments for paroxysmal nocturnal hemoglobinuria.
    Lee SE; Lee JW
    Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943
    [No Abstract]   [Full Text] [Related]  

  • 12. Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.
    Gurnari C; Nautiyal I; Pagliuca S
    Ther Clin Risk Manag; 2021; 17():1343-1351. PubMed ID: 34934322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Norm-based comparison of the quality-of-life impact of ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria.
    Schwartz CE; Stark RB; Borowiec K; Nolte S; Myren KJ
    Orphanet J Rare Dis; 2021 Sep; 16(1):389. PubMed ID: 34526067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
    Peipert JD; Kulasekararaj AG; Gaya A; Langemeijer SMC; Yount S; Gonzalez-Fernandez FA; Ojeda Gutierrez E; Martens C; Sparling A; Webster KA; Cella D; Tomazos I; Ogawa M; Piatek CI; Wells R; Sicre de Fontbrune F; Röth A; Mitchell L; Hill A; Kaiser K
    PLoS One; 2020; 15(9):e0237497. PubMed ID: 32886668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Rare Case of Paroxysmal Nocturnal Hemoglobinuria With Bilateral Renal Vein Thrombosis.
    Lodhi OUH; Sohail S; Hassan D
    Cureus; 2020 Jun; 12(6):e8806. PubMed ID: 32724752
    [TBL] [